锅炉翻修项目，其中包括：(i)新建一套150吨╱小时超高温超高压循环流化床锅炉，配套新供热装置设 施;(ii)建造烟气除尘和脱硝装置，重新使用现有的脱硫装置;(iii)建立新的除渣和输灰、装煤和除尘系统; (iv)建立新的全膜海水淡化水系统(部分重复使用现有组件);(v)安装热供仪表和控制系统，同时进行集成 控制改造;(vi)建设相关的综合自动化系统和更新塬有系统(包括厂房区域的排水和供水系统、供暖、通 风和空调(HVAC)系统以及相关的绿化及铺装)。 智通财经APP讯，大成生化科技(00809)发布公告，招标已于2025年7月14日成功收标，而长春大合(公司 全资附属公司)已于2025年7月31日与联合中标者东北电力及辽宁电力订立EPC合约。根据EPC合约，承 包商将负责锅炉翻修项目的项目工程设计、采购、施工、安装、校准及测试运行相关工作，最高代价为 人民币1.291亿元(包括提前竣工最高奖金)。 ...

Core Viewpoint - The company has successfully awarded an EPC contract for a boiler renovation project, which is essential for enhancing operational efficiency and competitiveness in the market [1][2] Group 1: Project Details - The EPC contract was signed on July 31, 2025, with a maximum cost of RMB 129.1 million, including potential early completion bonuses [1] - The boiler renovation project includes the construction of a new 150 tons/hour ultra-high temperature and ultra-high pressure circulating fluidized bed boiler, along with various supporting systems [1] - Additional components of the project involve the establishment of flue gas dust removal and denitrification systems, a new seawater desalination system, and upgrades to existing automation and control systems [1] Group 2: Strategic Importance - The renovation is necessary due to the outdated boiler facilities that have been in use for over 20 years, which limits the company's cost-effectiveness and sustainability [2] - The company primarily engages in the production and sale of corn refining products and biochemical products, and lacks the qualifications and capabilities for similar large-scale renovation projects [2] - By outsourcing the boiler renovation project to a qualified EPC contractor, the company aims to reduce administrative costs and select high-quality suppliers through competitive bidding [2]

00809 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因依賴該等內容而引致的任何損失承擔任何責任。 GLOBAL BIO-CHEM TECHNOLOGY GROUP COMPANY LIMITED * 有關以公開招標方式訂立的EPC合約的須予披露交易 以公開招標方式訂立EPC合約 茲提述本公司日期為二零二五年五月二十三日有關就EPC合約開始公開招標的公告。 以公開招標方式訂立EPC合約 茲提述本公司日期為二零二五年五月二十三日有關就EPC合約開始公開招標的公告。 誠如本公司日期為二零二五年五月二十三日的公告所披露，長春大合已就EPC合約發出招 標公告邀請投標者，該招標已於二零二五年五月二十六日開始。由於並無足夠的投標者 參與該招標，長春大合已分別於二零二五年六月三日（已於二零二五年六月二十三日截 止，無中標者）及二零二五年六月二十四日發出另外兩份招標公告，邀請投標者競投EPC 合約。於日期為二零二五年六月二十四日的招標公告中，為激勵承包商參加招標，已加 入提供的獎金的條款以獎勵提前竣工鍋爐 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因依賴該等內容而引致的任何損失承擔任何責任。 00809 涉及根據特別授權發行代價股份之 供應商債務重組安排 延遲寄發通函 茲提述大成生化科技集團有限公司（「本公司」）日期為二零二五年七月八日之公告（「該公 告」），內容有關涉及根據特別授權發行代價股份之供應商債務重組安排。除文義另有所 指外，本公告所用詞彙與該公告所界定者具有相同涵義。 由於需要額外時間編製及落實將納入通函（「通函」）的若干資料，誠如該公告所述，其應 載有（其中包括）(i)股份購買協議及其項下擬進行交易（包括重新收購及授出發行代價股份 之特別授權）之進一步資料；(ii)股東特別大會通告；及(iii)上市規則規定須予披露之其他 資料，預期通函寄發予股東的日期將延遲至二零二五年八月二十二日或之前。 承董事會命 大成生化科技集團有限公司 主席 王成 GLOBAL BIO-CHEM TECHNOLOGY GROUP COMPANY LIMITED * 香港，二零二五年七月三十一日 於本公告 ...

Group 1 - Dachen Biotech (00809.HK) announced a debt restructuring arrangement with suppliers, establishing a partnership to facilitate this process [1] - The debt-to-equity swap agreement involves suppliers converting a total debt of RMB 461.1 million into equity, resulting in approximately 28.98% ownership in Century Dachen [1][2] - The completion of the debt-to-equity swap is contingent upon obtaining all necessary regulatory approvals, including those from the Ministry of Commerce [2] Group 2 - The debt-to-equity swap agreement includes a lock-up provision, preventing suppliers from selling or encumbering their shares except for the purpose of the debt restructuring [2] - A discount of no less than 30% is anticipated on the debt, with expected net gains of at least HKD 190 million from the debt restructuring [3] - Following the completion of the equity swap, Century Dachen will remain a wholly-owned subsidiary of the company, with no overall impact on the company's equity in Century Dachen [3]

Core Viewpoint - The company has decided to restart the boiler renovation project at Changchun Dahe and will select a suitable EPC contractor through a public bidding process to carry out the renovation work [1][2]. Group 1: Project Details - The boiler renovation project at Changchun Dahe will be executed under an EPC contract, which includes project design, procurement, and construction responsibilities for the selected contractor [1]. - The bidding announcement for the EPC contract was issued on May 23, 2025, with the bidding period starting on May 26, 2025, and concluding on June 17, 2025 [1]. Group 2: Financial and Operational Context - Changchun Dahe has maintained normal operations throughout 2024, contributing significantly to the company's revenue [2]. - The existing boiler facilities at Changchun Dahe have been in use for over 20 years, utilizing medium/low-pressure boilers, which are less cost-effective compared to the high-temperature/high-pressure options widely used in China [2]. - The renovation aims to upgrade the boiler systems to reduce costs and enhance market competitiveness, aligning with the company's overall sustainability goals [2].

Core Viewpoint - The company, Dachen Biochemical Technology (00809), is actively engaging in strategic partnerships to enhance its capabilities in synthetic biology, particularly in the context of the Changchun Economic and Technological Development Zone initiative [1][2]. Group 1: Strategic Partnerships - Dachen Biochemical Technology's subsidiary, Changchun Hongcheng Biochemical Materials Technology Development Co., Ltd., has entered into a strategic cooperation framework agreement with Hefei Hechen Biotechnology Co., Ltd. to leverage their respective strengths in synthetic biology [2]. - The collaboration aims to focus on the industrial application of synthetic biology in the amino acid sector, combining Dachen's expertise in process optimization and cost control with Hefei Hechen's strengths in gene design and metabolic pathway optimization [2]. Group 2: Industry Development Initiatives - The Changchun Economic and Technological Development Zone is establishing a synthetic biology industry innovation development pilot area, with the goal of promoting high-quality industrial development in Northeast China [1]. - A key aspect of the initiative includes the signing of the Changxing Oasis Sub-Fund, which has been established with a capital of RMB 50 million, focusing on applications of synthetic biology in biomanufacturing, agricultural technology, and green energy [1]. Group 3: Research and Development Facilities - The strategic cooperation will utilize the research center and pilot facilities located at the company's Xinglongshan production base, which includes approximately 10,000 square meters of factory space and four research and development centers [2]. - The pilot platform's inauguration during the conference signifies a crucial step in bridging the gap between technological achievements and industrial application, particularly in biobased chemicals and medical materials [2]. Group 4: Current Operations Status - As of the announcement date, the company's Xinglongshan production base remains suspended from operations [3].

Group 1 - The core viewpoint of the news is that Dachen Biochemical Technology (00809.HK) has entered into a strategic cooperation framework agreement with Hefei Hechen Biotechnology Co., focusing on the development of synthetic biology applications in the amino acid sector [1][2] - The strategic cooperation aims to leverage the strengths of both parties in synthetic biology, combining Dachen's experience in technology scaling, process optimization, and cost control with Hefei Hechen's expertise in gene design and metabolic pathway optimization [1][2] - A pilot platform for synthetic biology will be established at Dachen's Xinglongshan production base, which includes approximately 10,000 square meters of research and development facilities, supporting the industrialization of bio-based chemicals and medical materials [2] Group 2 - The unveiling of the pilot platform during the conference signifies a crucial step in bridging the gap between technological achievements and industrial application, facilitating breakthroughs in the bio-based chemical and medical materials sectors [2] - Hefei Hechen is focused on integrating synthetic biology with advanced delivery technologies, developing bio-based chemicals, specialty amino acids, and high-value active ingredients, as well as offering solutions for beauty products and functional food applications [2]